Eph receptors and their Eph receptor-interacting (ephrin) ligands comprise a vital cell
communication system with several functions. In cancer cells, there was evidence of bilateral Eph
receptor signaling with both tumor-suppressing and tumor-promoting actions. As a member of the
Eph receptor family, EphB4 has been linked to tumor angiogenesis, growth, and metastasis, which
makes it a viable and desirable target for drug development in therapeutic applications. Many investigations have been conducted over the last decade to elucidate the structure and function of
EphB4 in association with its ligand ephrinB2 for its involvement in tumorigenesis. Although several EphB4-targeting drugs have been investigated, and some selective inhibitors have been evaluated in clinical trials. This article addresses the structure and function of the EphB4 receptor, analyses its possibility as an anticancer therapeutic target, and summarises knowledge of EphB4 kinase inhibitors. To summarise, EphB4 is a difficult but potential treatment option for cancers.